Milan - Italian BioXell SpA. recently purchased additional indications from Swiss pharmaceutical giant Roche for lead compound BXL 628 which, under the original agreement, was licensed to BioXell for benign prostatic hyperplasia (BPH), secondary hyperparathyroidism, transplant rejection and type-I diabetes. The compound has recently completed a phase-II trial in Italy for BPH.
Under the new agreement, Roche has granted BioXell exclusive worldwide development rights to BXL 628 for all non-topical and non-dermatological applications. Financial details of the agreement were not disclosed.
BioXell was founded in 2002 through a spin-out from Roche Milano Ricerche, a Roche institute focusing on chronic inflammatory diseases and autoimmunity.